rondecabtagene autoleucel

Phase 3Cell therapy

LLyell Immunopharma, Inc.

rondecabtagene autoleucel is one of 17 biologic programs targeting Large B-cell Lymphoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Large B-Cell LymphomaRecruiting

Relapsed Non-Hodgkin LymphomaRecruiting

Large B-Cell LymphomaPhase 3

Recruiting

Relapsed Non-Hodgkin LymphomaPreclinical

Recruiting

Competition

Competitive Landscape

18 competitors in Large B-Cell Lymphoma

#DrugCompanyPhaseTrials

Rituxan

Roche

Phase 3

5 2

Adriamycin

Pfizer

Phase 3

3 3

Oncovin

Eli Lilly

Phase 3

2 4

Cytoxan

BBaxter Healthcare Corporation

Phase 3

7 5

Rayos

RRoxane Laboratories

Phase 3

4 6

Golcadomide

Bristol-Myers Squibb

Phase 3

2 7

Fludara

Sanofi

Phase 2

3 8

Epkinly

Genmab

Phase 2

1 9

Fabhalta

BBellicum Pharmaceuticals

Phase 2

1 10

Zynlonta

Akero Therapeutics

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2031

PreclinicalRecruiting

Relapsed Non-Hodgkin Lymphoma

NCT05826535

Q1 2032

Phase 3Recruiting

Large B-Cell Lymphoma

NCT07188558

Clinical

Trials by Indication[1]

Relapsed Non-Hodgkin Lymphoma1 trial

A Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of Rondecabtagene Autoleucel, a CD19/CD20 Dual-Targeting Chimeric Antigen Receptor T-Cell Therapy in Participants With Aggressive B-Cell Non-Hodgkin Lymphoma

Recruiting·LLyell Immunopharma, Inc.·Preclinical·NCT05826535·270 enrolled

Large B-cell Lymphoma1 trial

A Phase 3 Randomized Controlled Trial of Rondecabtagene Autoleucel , an Autologous, Dual-targeting CD19/CD20 CAR T-Cell Product Candidate, Vs. Investigator's Choice of CD19 CAR T-Cell Therapy in Patients With Relapsed or Refractory Large B-Cell Lymphoma in the Second-line Setting

Recruiting·LLyell Immunopharma, Inc.·Phase 3·NCT07188558·400 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for rondecabtagene autoleucel. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — rondecabtagene autoleucel compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for rondecabtagene autoleucel. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Lyell Immunopharma, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Cell therapy[2]
Highest Phase: Phase 3[1]
Company: LLyell Immunopharma, Inc.

rondecabtagene autoleucel

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2031

Q1 2032

Trials by Indication[1]

Relapsed Non-Hodgkin Lymphoma1 trial

Large B-cell Lymphoma1 trial

References

Drug Info

Quick Facts

Related News